Clinical Trial Update: 5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia [Phase 4]

View source ↗

Summary

Phase 4 clinical trial investigating how 5-HT2A, DRD2, and COMT gene polymorphisms affect olanzapine plasma concentration in early-onset schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Early-onset Schizophrenia

Drugs mentioned

• olanzapine (olanzapine)

Snippet

Sponsor: Kunming Medical University | Conditions: Early-onset Schizophrenia | Phase 4 | Status: COMPLETED